FY2025 EPS Estimates for UTHR Increased by Cantor Fitzgerald

United Therapeutics Corporation (NASDAQ:UTHR) – Equities research analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of United Therapeutics in a research note issued on Wednesday, September 10th. Cantor Fitzgerald analyst O. Brayer now expects that the biotechnology company will earn $28.70 per share for the year, up from their prior estimate of $28.43. Cantor Fitzgerald has a “Overweight” rating and a $525.00 price target on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share.

A number of other research analysts have also issued reports on UTHR. Jefferies Financial Group upped their target price on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. UBS Group upped their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, September 4th. Wells Fargo & Company raised their target price on shares of United Therapeutics from $295.00 to $414.00 and gave the stock an “equal weight” rating in a research report on Wednesday, September 3rd. Morgan Stanley lowered their target price on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Finally, Oppenheimer increased their price target on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, September 5th. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $438.85.

United Therapeutics Stock Performance

United Therapeutics stock opened at $405.02 on Friday. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The company has a market capitalization of $18.27 billion, a price-to-earnings ratio of 15.81, a PEG ratio of 6.17 and a beta of 0.62. The stock has a fifty day moving average of $318.53 and a two-hundred day moving average of $307.56.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same period last year, the company earned $5.85 EPS. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $398.55, for a total value of $3,188,400.00. Following the transaction, the chief executive officer directly owned 130 shares in the company, valued at $51,811.50. This trade represents a 98.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $385.21, for a total value of $4,237,310.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $14,168,409.01. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 128,816 shares of company stock valued at $45,836,113. 10.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Chung Wu Investment Group LLC purchased a new stake in United Therapeutics during the second quarter worth approximately $29,000. WealthCollab LLC lifted its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. SVB Wealth LLC purchased a new stake in United Therapeutics during the 1st quarter worth $32,000. Finally, Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.